Divi's Laboratories Limited vs Jubilant Pharmova Limited
An objective side-by-side of DIVISLAB and JUBLPHARMA, both in Pharmaceuticals - Indian - Bulk Drugs: valuation, profitability, growth, balance sheet, ownership and share-price performance. Where one number is clearly better on its own terms (lower P/E, higher ROE), it is shaded. That is a description, not a recommendation.
Prices as of 2026-11-05 close
Latest results: DIVISLAB Jun 2026 · JUBLPHARMA Jun 2026
At a glance
- Divi's Laboratories Limited is the larger company by market value, about 17.9 times the size of Jubilant Pharmova Limited.
- On trailing earnings, Jubilant Pharmova Limited trades at the lower P/E (42.7 against 92.0).
- Divi's Laboratories Limited earns the higher return on equity (17.5% against 5.0%).
- Over three years Jubilant Pharmova Limited has grown profits faster (47% a year against 13%).
- Over the past year the share prices returned +52.4% (DIVISLAB) and -15.3% (JUBLPHARMA).
| Metric | Divi's Laboratories DIVISLAB |
Jubilant Pharmova JUBLPHARMA |
|---|---|---|
| Size and price | ||
| Market cap | ₹269,198 Cr | ₹15,002 Cr |
| Share price | ₹10,140.50 | ₹947.05 |
| Valuation | ||
| P/E | 92.03 | 42.69 |
| P/B | 16.06 | 2.12 |
| EV/EBITDA | 67.86 | 15.30 |
| PEG | 7.08 | 0.91 |
| Dividend yield | 0.3% | 0.5% |
| Profitability | ||
| ROE | 17.5% | 5.0% |
| ROCE | 22.0% | 9.0% |
| Operating margin | 35.3% | 14.1% |
| Sales (TTM) | ₹11,230 Cr | ₹8,607 Cr |
| Net profit (TTM) | ₹2,925 Cr | ₹351 Cr |
| Growth | ||
| Latest quarter sales YoY | +27.8% | +1385.3% |
| Latest quarter profit YoY | +65.5% | +3217.6% |
| Sales CAGR 3Y | +11.0% | +10.0% |
| Profit CAGR 3Y | +13.0% | +47.0% |
| Sales CAGR 5Y | +9.0% | +6.0% |
| Profit CAGR 5Y | +6.0% | -13.0% |
| Financial strength | ||
| Debt/Equity | 0.00 | 0.51 |
| Interest cover | 129.48 | 2.51 |
| Ownership | ||
| Promoter holding | 51.9% | 47.7% |
| Promoter change (4 qtrs) | +0.00 pp | +0.01 pp |
| Price performance | ||
| Return 1M | +6.18% | -4.26% |
| Return 3M | +20.89% | +2.42% |
| Return 1Y | +52.37% | -15.32% |
| Return YTD | +58.63% | -11.76% |
| Technical condition | ||
| Technical score | 94 | 63 |
| RS rating (1-99) | 92.00 | 60.00 |
| % vs 200-DMA | +37.34% | +0.39% |
| RSI (14) | 70.55 | 47.70 |
| % from 52-week high | -0.18% | -19.95% |
